Which hospital in China will use dotalizumab (Jemperli)?

Dotalizumab (Jemperli) is an immunotherapy drug, and its drug name is usually called Jemperli. The main function of this drug is to enhance the immune system's attack on cancer cells by inhibiting the signaling pathway on the PD-1 (programmed death 1) receptor. Dotalizumab is an immune checkpoint inhibitor that relieves the inhibition of T cells, allowing the immune system to more effectively identify and eliminate cancer cells.

Dotalizumab is not currently on the market in China, nor is it included in medical insurance. Domestic hospitals will not use it. Patients cannot purchase it domestically. They need to purchase dotalizumab through overseas channels. There are only original drugs available abroad, mainly from the United States, and the price is as high as about 50,000 yuan.

The clinical application of dotalizumab is mainly focused on the treatment of ovarian cancers with highly unstable microsatellite mismatches (dMMR) or deficient DNA mismatch repair (dMMR). This type of ovarian cancer often has extensive DNA damage and mutations, making it easier for the immune system to recognize and attack the cancer cells. Therefore, dotalizumab provides a new treatment option for patients with these specific types of ovarian cancer, especially when conventional treatments are ineffective or intolerable.

Dotalizumab is an important advance in the field of immunotherapy and represents a treatment option that has the potential to improve survival and quality of life for cancer patients. However, specific treatment options should be based on the patient's condition and the advice of a medical professional, and require close monitoring of the patient's health and potential side effects. The research and clinical application of dotalizumab continues to develop, bringing new hope to the field of cancer treatment.